Nasopharyngeal carcinoma - first-line treatment

Active Ingredient: Toripalimab

Indication for Toripalimab

Population group: only adults (18 years old or older)

Therapeutic intent: Curative procedure

Toripalimab, in combination with cisplatin and gemcitabine, is indicated for the first-line treatment of adult patients with recurrent, not amenable to surgery or radiotherapy, or metastatic nasopharyngeal carcinoma.

For this indication, competent medicine agencies globally authorize below treatments:

240 mg every 3 weeks until disease progression, unacceptable toxicity or up to a maximum duration of 24 months

For:

Dosage regimens

Intravenous, 240 milligrams toripalimab, once every 3 weeks, over the duration of up to 24 months.

Detailed description

The recommended dosing regimen of toripalimab is 240 mg every 3 weeks (Q3W) as an intravenous infusion over 60 minutes for the first infusion. If no significant infusion-related reactions occurred during the first infusion, the subsequent infusions may be administered over 30 minutes.

Treatment should continue until disease progression, unacceptable toxicity or up to a maximum duration of 24 months.

Dosage considerations

Toripalimab is for intravenous use only and must be administered by infusion. The first infusion should be administered over 60 minutes via an infusion pump through an in-line filter. If no infusion-related reactions occurred during the first infusion, subsequent infusions may be administered over 30 minutes.

When administered on the same day as chemotherapy, toripalimab should be administered prior to chemotherapy through a different intravenous line.

Active ingredient

Toripalimab
Toripalimab is a humanised IgG4 monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2, releasing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumour immune response. Binding of the PD-1 ligands, PD-L1 and PD-L2, to the PD-1 receptor found on T cells, inhibits T cell proliferation, cytokine production, and cytotoxic activity. Read more about Toripalimab

Related medicines

Summary of Product Characteristics (SPC) 2025: LOQTORZI Concentrate for solution for infusion

Structured Product Labeling (SPL/PLR) 2024: LOQTORZI Solution for injection

Develop a tailored medication plan for your case, considering factors such as age, gender, and health history

Ask the Reasoner

Liability Disclaimer : RxReasoner has utilized reasonable care in providing content and services that are accurate, complete and up to date. However, RxReasoner does not accept any responsibility or liability about it. The content and services of RxReasoner are for informational purposes only and they are not intended to be a substitute for the knowledge, expertise, skill, and judgment of physicians, pharmacists, nurses, or other healthcare professionals involved in patient care. RxReasoner offers no medical advice. Users are responsible for the use of the provided content. A shown indication or treatment should not be construed to indicate that the medication is safe, appropriate, or effective in any given patient or under any particular circumstances. The absence of an indication or treatment should not roule out the existence of other appropriate medications. Always seek the advice of a physician or other qualified health provider with any questions you may have regarding a medical condition or medicament. RxReasoner is not liable for any damages allegedly sustained arising out of the use of its content and services.